Potential antibody therapy restricts the growth of aggressive and treatment-resistant breast cancers
A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.
Noticias
MIT discovers amino acid that helps the gut heal itself
MIT scientists have found that an amino acid called cysteine can help the gut heal itself. In mouse studies, a cysteine-rich diet activated immune cells that release a molecule speeding up tissue repair in the small intestine. This process helped regen…
Understanding autoimmune neuromuscular diseases: Signs, causes & treatment
Autoimmune neuromuscular diseases may sound complex, but understanding them is the first step to getting the right care and support. Conditions such as Lambert-Eaton myasthenic syndrome (LEMS), myasthenia gravis (MG), and inclusion body myositis (IBM) …
A less invasive, more effective method to analyze immunotherapy efficacy
Immunotherapy has been one of the most promising advancements in cancer treatment. However, consistency in immunotherapy treatment effectiveness remains a formidable challenge. Now, Cancer Center at Illinois member Kun Wang, Binbin Wang, a post-doctora…
Immune cell pockets found in lymphoma tumors offer new targets for personalized therapies
By analyzing the tumor environment of diffuse large B-cell lymphoma (DLBCL), researchers from The University of Texas MD Anderson Cancer Center have identified seven distinct cellular microenvironments, providing a framework to develop therapies that w…
New genomic test could spare some people with melanoma from lymph node biopsy surgery
A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes—a finding that could guide treatment decisions and help many people avoid lymph node biopsy surge…
Existing drugs for tissue scarring could help avert melanoma relapses
Cellular changes that appear during melanoma and lead to treatment resistance can be reversed with drugs—potentially opening the door to new or more effective treatments for the deadly disease, according to new Cornell research.
Elironrasib may overcome resistance to prior KRAS G12C inhibition in non-small cell lung cancer
Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), including after prior treatment with KRAS G12C inhibitors and in the presence of features linked to KRAS inhibitor res…
Zenocutuzumab shows clinical benefit in rare bile duct cancer
Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, according to results from the…
Investigational antibody-drug conjugate shows clinical benefit against previously treated small cell lung cancer
Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the protein DLL3, demonstrated both safety and capacity to induce anticancer responses in patients with extensive-stage small cell lung …